(Article in Japanese) Rebouche CJ, Chenard CA
ARTEMIS-EMU was a double-blind, randomized, placebo-controlled trial in patients admitted to an Epilepsy Monitoring Unit [51]
Earlier this year, it notified doctors and patients about which symptoms to monitor, warning that anyone experiencing them should seek immediate medical attention
Thymosin Beta-4 also activates ILK (integrin-linked kinase), a key regulator of cell survival signaling downstream of integrins a mechanism discovered in the context of cardiac repair research
No insurance or membership fee is required
You may see some results, but the process will be slower, and you may experience more side effects